Why Valeant Pharmaceuticals Intl. Inc. Leaped the Wrong Direction
The bigger issue is whether or not Valeant's drug pricing practices will get a clean bill of health from regulators. Congress has been closely examining Valeant's buy-and-hike strategy of purchasing specialty therapies and immediately increasing their price by large factors. There may be no immediate answer or solution to this question for Valeant or investors, but if you believe in Valeant's growth-by-acquisition model and the cash flow it's derived from it, then this recent hiccup, while unpleasant, may be nothing but a blip over the long run.
A secret billion-dollar stock opportunity
The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here .
The article Why Valeant Pharmaceuticals Intl. Inc. Leaped the Wrong Direction originally appeared on Fool.com.
Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen nameTMFUltraLong, track every pick he makes under the screen nameTrackUltraLong, and check him out on Twitter, where he goes by the handle@TMFUltraLong.The Motley Fool owns shares of and recommends Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2016 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .